Somatic mutations in the genes encoding NRF2 (NFE2L2) and its inhibitor KEAP1 have been identified in various malignancies, including lung, esophageal, and skin squamous cell carcinomas. This evidence concerns the gene NFE2L2 and skin squamous cell carcinoma.